Cytogen Believes Patent Lawsuit Meritless
PRINCETON, N.J., March 17 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO - news) announced today that it has been served with a patent infringement suit by Immunomedics, Inc. The suit, filed in the U.S. District Court of New Jersey, alleges that Cytogen's ProstaScint© imaging agent for detection of prostate cancer, infringes Immunomedics' U.S. Patent No. 4,460,559. Cytogen believes that the suit is without merit.
The Immunomedics patent has now expired, and the suit does not affect the sale of any of the Company's products. The Company believes that this patent is unenforceable and invalid, and that it does not infringe this patent. The Company plans to defend itself aggressively. In addition, the Company has certain indemnification rights regarding this patent.
Cytogen Corporation, based in Princeton, New Jersey, is a biopharmaceutical company that develops new treatments and diagnostics for cancer and urological diseases. Cytogen has three products on the market including ProstaScint© imaging agent for prostate cancer, Quadramet© agent for treatment of pain from cancers that have metastasized to the bone, and OncoScint© imaging agent for colorectal and ovarian cancers. Cytogen also holds the intellectual property rights to PSMA (Prostate Specific Membrane Antigen), a unique antigen under development for immunotherapeutic and other approaches, particularly in the area of prostate cancer. AxCell Biosciences, a wholly owned subsidiary of Cytogen, is charting the proteome to develop a protein pathway database to identify novel drug targets. For information on Cytogen, including prescribing information regarding it approved products, visit the Company's web sites at www.cytogen.com and www.axcellbio.com.
Information in this press release which is not historical is forward looking and involves risks and uncertainties. Actual results may differ materially for various reasons, including risks of litigation and uncertainties surrounding the construction, interpretation, and enforcement of patent claims, and other factors discussed in the Company's filings with the Securities and Exchange Commission.
SOURCE: Cytogen Corporation
--------------------------------------------------------------------------------
More Quotes and News: Cytogen Corp (NasdaqNM:CYTO - news)
Related News Categories: biotech, medical/pharmaceutical |
